shRNA-mediated knockdown of IGF2BP1 in melanoma, neuroblastoma, and CRC cell lines increases sensitivity to a variety of chemotherapeutic drugs, and IGF2BP1 expression is elevated in chemoresistant CRC tumors [41, 53–55]. This evidence concerns the gene IGF2BP1 and melanoma.